Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 15/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | BCL2 | P10415 | 1/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7961076 | 0.80 | BACE1 (0.55) | BACE1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL447340 | 0.79 | BACE1 (0.45) | BACE1BCL2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL447140 | 0.77 | BACE1 (0.45) | BACE1BCL2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL10261540 | 0.76 | BACE1 (0.49) | BACE1GAABACE2GSK3BDYRK1A | |
| SCHEMBL16230150 | 0.75 | BACE1 (0.84) | BACE1 | |
| SCHEMBL15976459 | 0.75 | BACE1 (0.47) | BACE1BCL2 | |
| SCHEMBL7889288 | 0.72 | BACE1 (1.00) | BACE1 | |
| SCHEMBL30105758 | 0.72 | BACE1 (0.48) | BACE1BACE2 | |
| SCHEMBL9611572 | 0.71 | BACE1 (0.49) | BACE1 | |
| SCHEMBL568040 | 0.70 | BACE1 (0.56) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | APP, BACE1, PSEN1 | BACE1 2/4885GAA 287/4885BCL2 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.